Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
BACKGROUND
Recent reports and a previous randomized trial conducted at the authors' institution suggested that a lower risk subset of children with febrile neutropenia under chemotherapy might benefit of an oral antibiotic outpatient approach.


METHODS
The objective of this study was to test the efficacy of oral ciprofloxacin in the treatment of lower risk febrile neutropenia (LRFN) in children treated for malignant diseases. From November 1998 to December 1999, 93 episodes of LRFN in 87 children (median age, 5.5 years; range, 0.9-15.8 years) were included in a prospective randomized controlled single institution trial. Inclusion criteria included fever (> 38 degrees C), severe neutropenia (absolute neutrophil count, < 500/mm(3)), and lower risk features (e.g., absence of severe comorbidity factors, good clinical condition, negative blood cultures, control of local infection, prediction of a period of neutropenia less than 10 days after admission, and compliant parents). After 24 hours of a single intravenous ceftriaxone (100 mg/kg) plus amikacin (15 mg/kg) and completed risk assessment workup, patients were discharged and randomly allocated to two groups. Group A (48 episodes) received ciprofloxacin 20 mg/kg/day orally (p.o.) every 12 hours for 6 days. Group B (45 episodes) received intravenous ceftriaxone plus amikacin for 2 days more followed by cefixime (8 mg/kg/day p.o.) every 24 hours for 4 additional days. Failure was defined as the need of a second hospitalization during the same episode.


RESULTS
Most of the patients (59% in Group A and 52% in Group B) were treated for malignant solid tumors. Fifteen (31%) children in Group A and 15 (33%) in Group B presented with fever of unknown origin (P value was not significant). No significant differences were found in sites of initial infection between both groups. Overall results in this study were excellent. Only one patient with respiratory failure was detected in Group B, who did well with secondary treatment.


CONCLUSIONS
In febrile neutropenic children after anticancer therapy and lower risk features, oral ciprofloxacin for 6 days after 24 hours of intravenous ceftraxione plus amikacin appears to be as efficacious as intravenous ceftriaxone plus amikacin for 2 days more followed by cefixime for 4 additional days. These results contribute to strengthen the concept of LRFN.
Paganini
H
H
Department of Infectious Diseases and Epidemiology, Hospital de Pediatría Profesor Dr. J.P. Garrahan, Buenos Aires, Argentina. hpaganini@intramed.net.ar
Rodriguez-Brieshcke
T
T
Zubizarreta
P
P
Latella
A
A
Firpo
V
V
Casimir
L
L
Armada
A
A
Fernández
C
C
Cáceres
E
E
Debbag
R
R
D000284:Administration, Oral; D000293:Adolescent; D000583:Amikacin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D020682:Cefixime / Q000008:administration & dosage; D002511:Cephalosporins / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000008:administration & dosage*; D005260:Female; D005334:Fever / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D005335:Fever of Unknown Origin / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D012307:Risk Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D002511:Cephalosporins; D002939:Ciprofloxacin; D000583:Amikacin; D020682:Cefixime